163 related articles for article (PubMed ID: 36624015)
21. Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.
Jawhar M; Naumann N; Schwaab J; Baurmann H; Casper J; Dang TA; Dietze L; Döhner K; Hänel A; Lathan B; Link H; Lotfi S; Maywald O; Mielke S; Müller L; Platzbecker U; Prümmer O; Thomssen H; Töpelt K; Panse J; Vieler T; Hofmann WK; Haferlach T; Haferlach C; Fabarius A; Hochhaus A; Cross NCP; Reiter A; Metzgeroth G
Ann Hematol; 2017 Sep; 96(9):1463-1470. PubMed ID: 28725989
[TBL] [Abstract][Full Text] [Related]
22. Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms.
Gotlib J
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):34-46. PubMed ID: 36485158
[TBL] [Abstract][Full Text] [Related]
23. Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms.
Naumann N; Schwaab J; Metzgeroth G; Jawhar M; Haferlach C; Göhring G; Schlegelberger B; Dietz CT; Schnittger S; Lotfi S; Gärtner M; Dang TA; Hofmann WK; Cross NC; Reiter A; Fabarius A
Genes Chromosomes Cancer; 2015 Dec; 54(12):762-70. PubMed ID: 26355392
[TBL] [Abstract][Full Text] [Related]
24. Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement.
Shao H; Wang W; Song J; Tang G; Zhang X; Tang Z; Srivastava J; Shah B; Medeiros LJ; Zhang L
Leuk Res; 2020 Dec; 99():106460. PubMed ID: 33166908
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group.
Shomali W; Colucci P; George TI; Kiladjian JJ; Langford C; Patel JL; Reiter A; Vannucchi AM; Gotlib J
Leukemia; 2023 May; 37(5):981-987. PubMed ID: 37076693
[No Abstract] [Full Text] [Related]
26. Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia.
Winkelmann N; Hidalgo-Curtis C; Waghorn K; Score J; Dickinson H; Jack A; Ali S; Cross NC
Leuk Lymphoma; 2013 Jul; 54(7):1527-31. PubMed ID: 23186533
[TBL] [Abstract][Full Text] [Related]
27. Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1.
Vega F; Medeiros LJ; Bueso-Ramos CE; Arboleda P; Miranda RN
Am J Clin Pathol; 2015 Sep; 144(3):377-92. PubMed ID: 26276769
[TBL] [Abstract][Full Text] [Related]
28. Pemigatinib for the treatment of myeloid/lymphoid neoplasms with
Freyer CW; Hughes ME; Carulli A; Bagg A; Hexner E
Expert Rev Anticancer Ther; 2023 Apr; 23(4):351-359. PubMed ID: 36927350
[TBL] [Abstract][Full Text] [Related]
29. Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2.
Pozdnyakova O; Orazi A; Kelemen K; King R; Reichard KK; Craig FE; Quintanilla-Martinez L; Rimsza L; George TI; Horny HP; Wang SA
Am J Clin Pathol; 2021 Feb; 155(2):160-178. PubMed ID: 33367495
[TBL] [Abstract][Full Text] [Related]
30. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
[TBL] [Abstract][Full Text] [Related]
31. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.
Maiti A; Franquiz MJ; Ravandi F; Cortes JE; Jabbour EJ; Sasaki K; Marx K; Daver NG; Kadia TM; Konopleva MY; Masarova L; Borthakur G; DiNardo CD; Naqvi K; Pierce S; Kantarjian HM; Short NJ
Acta Haematol; 2020; 143(6):567-573. PubMed ID: 32289808
[TBL] [Abstract][Full Text] [Related]
32. Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?
Megías-Vericat JE; Ballesta-López O; Barragán E; Martínez-Cuadrón D; Montesinos P
Blood Rev; 2020 Nov; 44():100675. PubMed ID: 32147087
[TBL] [Abstract][Full Text] [Related]
33. Application of tyrosine kinase inhibitors as a promising targeting treatment for myeloproliferative neoplasms --- review.
Wei M; Gao CJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):1064-70. PubMed ID: 21867645
[TBL] [Abstract][Full Text] [Related]
34. Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review.
Savage N; George TI; Gotlib J
Int J Lab Hematol; 2013 Oct; 35(5):491-500. PubMed ID: 23489324
[TBL] [Abstract][Full Text] [Related]
35. SOHO State of the Art Updates and Next Questions | Myeloid/Lymphoid Neoplasms with Eosinophilia and Gene Rearrangements: Diagnostic Pearls and Pitfalls.
Kim AS; Pozdnyakova O
Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):643-651. PubMed ID: 35478091
[TBL] [Abstract][Full Text] [Related]
36. Myeloid neoplasm with ETV6::ACSl6 fusion: landscape of molecular and clinical features.
Su Z; Liu X; Hu W; Yang J; Yin X; Hou F; Wang Y; Zhang J
Hematology; 2022 Dec; 27(1):1010-1018. PubMed ID: 36069745
[TBL] [Abstract][Full Text] [Related]
37. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
Metzgeroth G; Walz C; Score J; Siebert R; Schnittger S; Haferlach C; Popp H; Haferlach T; Erben P; Mix J; Müller MC; Beneke H; Müller L; Del Valle F; Aulitzky WE; Wittkowsky G; Schmitz N; Schulte C; Müller-Hermelink K; Hodges E; Whittaker SJ; Diecker F; Döhner H; Schuld P; Hehlmann R; Hochhaus A; Cross NC; Reiter A
Leukemia; 2007 Jun; 21(6):1183-8. PubMed ID: 17377585
[TBL] [Abstract][Full Text] [Related]
38. Chronic eosinophilic leukemia, NOS with t(5;12)(q31;p13)/ETV6-ACSL6 gene fusion: a novel variant of myeloid proliferative neoplasm with eosinophilia.
Su RJ; Jonas BA; Welborn J; Gregg JP; Chen M
Hum Pathol (N Y); 2016 Sep; 5():6-9. PubMed ID: 27458550
[TBL] [Abstract][Full Text] [Related]
39. Myeloid/lymphoid neoplasms with eosinophilia/ basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase inhibition.
Yao J; Xu L; Aypar U; Meyerson HJ; Londono D; Gao Q; Baik J; Dietz J; Benayed R; Sigler A; Yabe M; Dogan A; Arcila ME; Roshal M; Zhang Y; Mauro MJ; Xiao W
Haematologica; 2021 Feb; 106(2):614-618. PubMed ID: 32299902
[No Abstract] [Full Text] [Related]
40. BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia.
He R; Greipp PT; Rangan A; Mai M; Chen D; Reichard KK; Nelsen LL; Pardanani A; Hanson CA; Viswanatha DS
Cancer Genet; 2016 May; 209(5):223-8. PubMed ID: 27134074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
